Abstract
Desmopressin (1-deamino-8-D-arginine vasopressin (DDAVP)) has been shown to be an effective treatment option when administered both intravenously [1,2] and subcutaneously [3] to children with inherited bleeding disorders. We demonstrate here, both the efficacy and acceptability of a new intranasal DDAVP preparation, providing a cost effective treatment with good outcomes for children with bleed disorders.
MeSH terms
-
Administration, Intranasal
-
Adolescent
-
Child
-
Cohort Studies
-
Deamino Arginine Vasopressin / administration & dosage*
-
Deamino Arginine Vasopressin / adverse effects
-
Dose-Response Relationship, Drug
-
Female
-
Hemophilia A / drug therapy*
-
Hemorrhage / etiology
-
Hemorrhage / prevention & control*
-
Hemostatics / administration & dosage*
-
Hemostatics / adverse effects
-
Humans
-
Male
-
Treatment Outcome
Substances
-
Hemostatics
-
Deamino Arginine Vasopressin